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Abstract 
Since the findings of a Fatal Accident Inquiry (FAI) in 2010, clinicians working in Scotland 
have been advised to discuss the risk of Sudden Unexpected Death in Epilepsy (SUDEP) with 
patients immediately or soon after a diagnosis of epilepsy is made.  A thematic analysis was 
used to describe the experiences discussing SUDEP of 10 clinicians (six Consultant 
Neurologists and four Neurology Registrars) working in Scotland.  Contrary to previous 
research, clinicians appear to be routinely discussing SUDEP in a standardised fashion with 
newly diagnosed patients and the FAI appears to have instigated this change in practice.  
Clinicians are ambivalent about the practice and whether this is a Breaking Bad News (BBN) 
experience.  Clinicians appear to anticipate that patients will be anxious or distressed 
discussing SUDEP, despite their experiences that patients do not react this way.  There are 
further concerns that the pressure to discuss SUDEP, as a result of the FAI, hinders effective 
communication of the SUDEP message.  Implications for guideline development are 
discussed. 
 
Highlights 
 A qualitative examination of Neurologists’ experiences discussing SUDEP with 
patients 
 Clinicians state they are regularly discussing SUDEP with patients who have newly 
been diagnosed with epilepsy 
 Clinicians feel ambivalent about discussing SUDEP despite indicating the experience 
is not distressing for themselves, or apparently for their patients 
 Clinicians raise concerns about being under pressure to discuss SUDEP, and the 
implications this has for the quality of their communication 
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 1. Introduction 
 
Epilepsy is a chronic long term neurological condition affecting approximately 1 percent of 
the population and is associated with significant morbidity and mortality. However, it has 
been suggested that in the 20th century the risk of death due to epilepsy became minimised 
then denied by the medical community [1].  It was not until 1996 that the term ‘Sudden 
Unexpected Death in Epilepsy’ (SUDEP) was proposed [2].  SUDEP is defined as “sudden, 
unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in a patient 
with epilepsy, with or without evidence for a seizure, and excluding status epilepticus, where 
the autopsy examination does not reveal a toxicological or anatomical cause of death.” 
 [3, p66]. SUDEP is more common in younger individuals, with an incidence rate of 
approximately 1 in 1000 individuals with epilepsy [9]. The mechanism of SUDEP is not fully 
understood but may involve impaired autonomic, cardiac and respiratory function [4]. 
Individuals with epilepsy may potentially reduce the risk of SUDEP by lowering seizure 
frequency and by compliance with anti-seizure medications [5, 6].   
 
Harden, et al [13] reported young adults with epilepsy were keen to have a SUDEP 
discussion with their clinician preferably during the session they were diagnosed with 
epilepsy, or soon thereafter.  Parents of children with epilepsy also wish to be informed about 
SUDEP during their first discussion of epilepsy [14, 15].  Despite the literature and 
guidelines, it has been reported that clinicians are not regularly having SUDEP discussions 
with their patients.  For example, Morton, et al [16] analysed 387 questionnaires when 
surveying the practice habits of UK based Neurologists. Approximately 70% discussed 
SUDEP with ‘very few’ or ‘none’ of their patients.  Similarly, of 1200 American and 
Canadian Neurologists surveyed in 2012, less than 7% reported routinely discussing SUDEP 
with all patients [18] and a perceived negative reaction to discussions of SUDEP was 
common.   
 
Miller, Young, Friedman, Buelow, and Devinsky [19] used a qualitative approach to 
understand the practice of American clinicians when discussing SUDEP.  A theme of ‘moral 
accountability’ was present when clinicians expressed a reluctance to discuss SUDEP with 
their patients if they felt it was ‘morally wrong to give information about a complication that 
is poorly understood and difficult to prevent’ [19, p40].  Clinicians wanted to wait until 
rapport was built with their patients before discussing SUDEP and there was a reluctance to 
discuss SUDEP if all treatment options had been tried.     
 
Clinicians may fear a negative response from patients during breaking bad news (BBN) 
experiences, and clinicians can feel responsible for the bad news [20, 21].  BBN is especially 
difficult when there are limited options for treatment [22] or if there is a feeling of 
inadequacy treating an uncontrollable disease [23].  
 
1.1 National Guidelines and Context 
 
National Institute of Clinical Excellence (NICE) guidelines in the United Kingdom specify 
that following a first seizure, patients should see a specialist in the management of epilepsy 
[10].  Discussion regarding SUDEP with patients should contain ‘tailored information’ that 
‘takes account of the small but definite risk of SUDEP’ [10, Section 1.3.13, p16] However, 
access to this information should depend on the certainty of the diagnosis [10].  The 
American Epilepsy Society and the Institute of Medicine recommend that the increased risk 
of death associated with epilepsy be disclosed to patients [11, 12].  
  
In Scotland, where this research was conducted, Neurologists are also likely to be aware of a 
Sheriff-led Fatal Accident Inquiry (FAI) into two patient deaths in 2010 [26]. This 
established that two Scottish Health Boards were at fault for not informing these patients, and 
their parents, of the risk of SUDEP and that the ‘vast majority’ of patients should be informed 
about SUDEP upon being diagnosed with epilepsy or it should be recorded as to why this did 
not occur. An indication of the impact of this on the clinical practice of Neurologists can be 
seen by comparing a study conducted on medical records from 2004 to 2009 which identified 
that only 4% of 345 patients with epilepsy had a documented discussion of SUDEP in their 
records [17] with one conducted in 2013/14 which found that newly diagnosed young adults 
with epilepsy in Scotland had been uniformly informed about SUDEP following diagnosis 
[13, 24]. Scottish Intercollegiate Guidelines Network (SIGN) guidelines published in 2015 
advise that: ‘Counselling about the risks of sudden unexpected death in epilepsy should be 
considered for patients with epilepsy at an appropriate time for the patient and by an 
appropriate healthcare professional’ [27, p55].  
 
 
1.2 Aim 
 
To explore the experiences of Neurologists when discussing SUDEP with their patients and 
develop themes to account for these.  
 
The objectives of the research were to understand how the participants discussed SUDEP; 
how the participants felt when discussing SUDEP (including their thoughts on the impact of 
the discussion on patients); how they classified good and bad experiences when discussing 
SUDEP; methods of support utilised or envisioned; feelings about the legal/legislative 
context to discuss SUDEP and reflections on the practice; as well as assessing if similar 
themes identified in previous research were present [19]. 
 
2. Material and Methods 
 
2.1 Participants 
Consultant Neurologists and Registrar Doctors were considered for inclusion in the research 
(typically, Registrar Doctors who specialise in Neurology will have at least 4 years of clinical 
training in neurology before becoming a consultant).   
 
2.2 Recruitment and Interview Procedures 
Ethical approval was obtained from the school of Medical, Veterinary and Life Sciences at 
the University of Glasgow.  Clinicians were asked to participate following the researcher 
attending a departmental educational meeting of the West of Scotland Neurology Service (a 
group of Consultant Neurologists and Registrar Doctors).  A set of questions was developed 
by examining the previous literature and consulting with the Consultant Neurologist Field 
Supervisor (Appendix A).  Supplemental questions were asked based on the content of the 
interviews.   
 
2.3 Qualitative Design and Research Procedures 
A thematic analysis was conducted as previous research had used a similar approach to 
investigate the experiences of American clinicians’ practice of discussing SUDEP [19] and it 
was felt a comparison of practice would be useful.  The researcher used an inductive 
approach to analysis [29] and themes were primarily identified using a semantic approach; 
 taking themes from the explicit statements of participants.  The research procedure was 
conducted in line with Braun and Clarke’s [29] proposed six phases of thematic analysis.  
Data was anonymised and stored in line with the University of Glasgow’s policy on 
confidential data.  After the 8th interview no novel themes were found indicating that data 
saturation had occurred.  
 
2.4 Reflexivity 
Blumer [32] describes the assumptions and prior knowledge of a researcher as ‘sensitizing 
concepts’.  Therefore, the researcher’s background as a Trainee Clinical Psychologist is 
relevant.  Issues of support and the psychological impact of breaking bad news were areas of 
interest to the researcher.  The researcher’s own thoughts and interpretations were monitored 
by keeping a reflective log throughout the research process.   
 
 
3. Results 
Six Consultant Neurologists and four Registrar Doctors participated in the research.  The 
participant details are shown in table 1.  
 
Participant 
Number 
Role Number of years 
practising in current 
role 
Length of 
interview (mins) 
Ss 1 Registrar Doctor 5 34.22 
Ss 2 Registrar Doctor 4 36.36 
Ss 3 Consultant Neurologist 16 32.33 
Ss 4 Consultant Neurologist 15 33.11 
Ss 5 Registrar Doctor 2 44.07 
Ss 6 Registrar Doctor 4 39.54 
Ss 7 Consultant Neurologist 10 44.07 
Ss 8 Consultant Neurologist 3 35.25 
Ss 9 Consultant Neurologist 7 25.20 
Ss 10 Consultant Neurologist 2.5 27.24 (Phone 
interview) 
Table 1: Participant characteristics and interview length 
 
Five main themes accounted for the experiences of clinicians when discussing SUDEP: The 
SUDEP Protocol; Diffusion of the FAI; Breaking Good News – ambivalence discussing 
SUDEP; Incorrectly Anticipating Distress; and Pressure hinders effective communication.   
 
3.1 The SUDEP Protocol 
Clinicians regularly inform patients about SUDEP with only slight variations in practice 
noted.  Clinicians appear to engage in two types of SUDEP conversation; those for patients 
with newly diagnosed epilepsy (shown diagrammatically in Appendix B) and those for 
chronic, uncontrolled epilepsy patients. 
For chronic uncontrolled epilepsy patients, the SUDEP conversation was invariably used as a 
means of emphasising the risks associated with poor epilepsy control and in an attempt to 
encourage medication adherence: 
 ‘so, as I said, the two patient groups - patients who have chronic epilepsy you are 
seeing back and they have poor control and you talk about it.’ (Registrar, Ss2) 
 
Sometimes this conversation would occur with people with long standing epilepsy because 
they had never been made aware of SUDEP: 
‘well there are many patients with long standing epilepsy who may have been 
diagnosed in the days when SUDEP wasn’t discussed but if a long-standing patient 
were to bring up concern about their risks of seizures or potential of harm then we 
would have a discussion about that as well.’ (Consultant, Ss3) 
 
Unlike chronic epilepsy patients, clinicians appear to regularly discuss SUDEP with newly 
diagnosed patients: 
‘in the last couple of years or the last few months when I was doing first seizure 
clinics perhaps - almost every new patient, yeah.’ (Registrar, Ss6)  
 
There was one very common exception to this rule - the topic of SUDEP is often not 
mentioned if the patient appears distressed or anxious about the epilepsy diagnosis.  
Clinicians noted that they will make notes to discuss SUDEP at the next appointment or they 
rely on Epilepsy Nurses to discuss SUDEP: 
‘and if they are very anxious during the first consultation I usually do not tell them 
regarding the diagnosis – regarding the SUDEP risk.’ (Consultant, Ss8) 
‘I heavily rely on my follow-up appointment with nurses where they discuss it far 
better than me I think, I believe.’ (Registrar, Ss5) 
 
Clinicians usually raise the issue of SUDEP first.  It was rarer for a patient to initiate a 
conversation about SUDEP following diagnosis: 
 ‘I've certainly seen some patients who have asked about it.  Um, you know I have 
had, you do get informed patients.’ (Registrar, Ss1) 
‘Um, well at new diagnosis, that's uncommon.’ (Consultant, Ss3) 
 
Clinicians often raise the topic of SUDEP towards the end of the diagnosis appointment: 
‘…towards the end, generally.  It's usually the last thing we talk about.’ (Consultant, 
Ss4) 
 
There is often a ‘script’ employed which contains the same information and similar phrasing: 
‘It’s probably a personal script I’m not sure I don’t know if everybody does that, yes.’ 
(Registrar, Ss6) 
 
 The information tended to include risk factors for SUDEP and it was common to emphasise 
that the risk of SUDEP is low and modifiable.   
‘you can explore that a bit further and say yes there is so much risk but it varies and 
the risk is higher in people who have persistent seizures and it’s important that you 
take your medications and control it and so on.’ (Consultant, Ss7) 
 
Many clinicians noted that they will not actually use the term SUDEP, preferring to state 
there was a risk of harm: 
 ‘What I have been doing is discussing that epilepsy can potentially cause serious 
harm but not quite use the ‘death’ word straight away.’ (Consultant, Ss7) 
 
SUDEP conversations, or the lack of them, were commonly documented to the GP. 
‘we will either refer you to the nurse specialist who’ll cover some of it and if not it 
will be covered in the next medical clinic. But I’ll try and document that as much as 
possible that it’s not done.’ (Registrar, Ss6) 
 
3.2 Diffusion of the FAI into practice 
Clinicians were aware of the FAI and some explicitly noted their thoughts and feelings 
regarding the ruling having read the inquiry: 
‘I don't want to point any direction against the sort of judge or the individual people 
or giving evidence but I don't think that was an amazingly useful event that ruling.’ 
(Registrar, Ss1) 
‘it was only after the Sheriff’s ruling a few years ago that it kind of became 
mandatory to bring up SUDEP with patients at the point of diagnosis or soon 
thereafter.’ (Consultant, Ss3) 
 
Although others expressed a more vague understanding of the FAI, everyone was aware of its 
implications: 
‘I think there have been rulings, but I wouldn’t be able to know the specifics of it, to 
say that we should all be informing and making [SUDEP] a priority to discuss.’ 
(Consultant, Ss9) 
 
The suggestion is that the practice of discussing SUDEP has been heavily influenced by the 
FAI ruling. This was in contrast to the impact of guidelines on SUDEP discussions - 
Clinicians were aware that guidelines relating to SUDEP practice existed but universally 
these had not been read. 
The FAI appears to have influenced practice by three mechanisms: initial neurology training, 
teaching days, and discussions with colleagues.  Both Registrars and recent Consultants noted 
that their practice of discussing SUDEP was influenced by their training in neurology: 
 ‘[my practice] is from my training days itself- I‘ve not read any guidelines but from 
the training days itself.’ (Consultant, Ss8) 
‘I think there were a few training sessions that I had attended last time when we were 
in ______teaching training day.’ (Registrar, Ss5) 
 
However, the greater influence on practice appeared to be exerted from colleagues, training 
and team discussions: 
‘I’ve gone to outside meetings and … those kind of things. And we’ve had epilepsy 
training days and we have a monthly training day in epilepsy perhaps comes once a 
year or things like that.’ (Consultant, Ss6) 
‘Meetings mostly yes - so reasonably formal departmental meetings.’ (Consultant, 
Ss9) 
‘[I learn it] from peers and epilepsy meetings.’ (Consultant, Ss3) 
 
3.3 Breaking Good News – ambivalence discussing SUDEP 
Individual clinicians expressed both their support and dissatisfaction with the practice of 
discussing SUDEP with newly diagnosed patients.  This ambivalence extended to the benefits 
to patients, the feelings regarding the FAI, and whether it is a Breaking Bad News experience 
or not.  In general clinicians stated that SUDEP was an important topic to discuss and patients 
should be well informed about their condition:  
 ‘I think the practice should be that it is important that the patient has all the 
information of their condition.’ (Consultant, Ss7)  
 
Many clinicians viewed SUDEP as a positive topic to discuss as it could increase medication 
adherence and meant that risk issues could be addressed: 
‘I think particularly if someone is swithering about compliance for medication – then 
I think a discussion of SUDEP can make them more adherent to the 
recommendations.’ (Consultant, Ss10) 
‘I want to frame it and structure it in a way that they think that compliance, lifestyle 
modification - if I do these two things well from my end then, actually, I am working 
towards less risk of coming to harm with these seizures. I want to bring a positive 
approach towards it.’ (Registrar, Ss5) 
 
An alternative feeling was also commonly expressed: 
‘I think there is an argument for should you discuss it should you not and clearly the 
court has made a decision and that's…but I think there is still an argument as to 
whether patients should be burdened by this worry’ (Consultant, Ss4). 
‘I think that the guideline that you tell everyone um leaves slightly at the discretion of 
the clinician.  And it’s a bit like any other guideline it’s a one size does not always fit 
all.  So I think it might be clinically appropriate to leave that to a subsequent 
 consultation to discuss.  Particularly if someone is upset having received a diagnosis 
of epilepsy.’  (Consultant, Ss10) 
 
Clinicians were unaware of the impact of discussing SUDEP with patients on their behaviour 
however they hoped that it might influence them positively:   
‘they probably contribute to good compliance and you know, possibly, they lead to 
more regular lifestyles and avoidance of binge drinking and other drugs and, I don't, I 
have no evidence to prove it but that’s the hope.’ (Consultant, Ss3) 
‘would hope it would make a difference to them is for them to take control of their 
condition and try and you know as I say get regular sleep, get the regular meals, 
avoid alcohol in excess, avoid drugs and take their medication that's what I'm hoping 
for.’ (Registrar, Ss2)   
 
Clinicians were divided as to whether they considered discussing SUDEP a BBN experience: 
‘no I don't think it's breaking bad news because it's not happened to them it’s just, 
you're just telling them about a potential risk and you've already gone through a lot of 
potential risks about epilepsy by that stage as well.’ (Registrar, Ss2) 
 ‘sort of, yeah, it's an educational thing.  Sort of breaking bad news.’ (Registrar, Ss1) 
‘I’d say it’s breaking good news you know there is this risk but it’s usually very, very 
low.’ (Consultant, Ss9) 
 
Clinicians noted that they had not needed or considered personal support for any conversation 
about SUDEP with patients.  Support could come in the form of discussions with colleagues 
or supervisors however it seemed rare for clinicians to do this. 
 
3.4 Falsely Anticipating Distress 
Clinicians stated that they were likely to cause anxiety by discussing SUDEP.  There were 
suggestions that clinicians were unduly worried about what the reaction might be from their 
patients: 
‘but I think it’s, if it was said to me I think it would be something that would sit you 
know if I had epilepsy and somebody told me 'you could go to sleep and have a 
seizure and not wake up' or 'you could have seizure and die from that' I suppose that 
would worry me, a lot.’ (Consultant, Ss4) 
‘and then very softly say the word death - because it’s frightening … [later on] I think 
that is more fear in the medics approaching this topic rather than in patients 
discussing this.’ (Registrar, Ss5) 
 
Interestingly, there was only one account of a patient reacting badly to the SUDEP 
discussion.  No other clinician had encountered a bad reaction from any patient when 
 discussing SUDEP.  In contrast, the general picture is that patients react calmly perhaps only 
occasionally expressing surprise: 
‘um so maybe slight surprise - not people getting upset though I don't think in my 
experience.’ (Registrar, Ss2) 
‘I’ve not seen any patient giving any anxious reactions so far.’ (Consultant, Ss8) 
 
There was some surprise expressed at the fact that patients react so calmly to SUDEP 
information and some suggestions as to why this is the case.  Clinicians felt that the epilepsy 
diagnosis, or the impact of the condition on their lifestyle, was more distressing than 
information about SUDEP: 
‘I think the majority, again, 4 in 5 will respond, pretty surprisingly, without anything. 
They will just take that as factual information.’ (Registrar, Ss6) 
 ‘often the implications of the seizure on their driving activity and other things is of 
greater concern to them than what is a relatively small risk [of SUDEP].’ 
(Consultant, Ss10) 
 
Clinicians suggested that the cautious approach clinicians take may result in the settled 
manner patients receive the news.  The suggestion was that their way of discussing SUDEP 
reduced patients’ anxieties: 
‘Uh, I tell in a very smooth manner so that it does not hurt or does not make them 
very anxious.’ (Consultant, Ss8) 
‘I think to be honest I have never seen it too positive or too negative. There is one 
standard conversation. And I don’t know if maybe I am getting it too easy (laughing) 
or, if it’s just me.’ (Registrar, Ss5) 
 
In general clinicians do not find discussing SUDEP with patients an anxiety provoking 
experience: 
‘Um…I feel happy talking about it, I feel comfortable talking about it.’ (Registrar, 
Ss2) 
 
There were suggestions that the initial change of practice brought about as a result of the FAI 
had been anxiety provoking, however, patients’ reactions alleviated this anxiety: 
‘Initially I used to be hesitant but nowadays because it’s become routine and after 
observing the reaction from the patient because it’s not an anxiety reaction it is a – 
they feel it is something like expected.’ (Consultant, Ss8) 
 
3.5 Pressure hinders effective communication 
Despite reporting that SUDEP is not a distressing experience for them, clinicians did not 
report universal satisfaction with the requirement to discuss it.  It appears that pressure affects 
 clinicians’ ability to communicate SUDEP information in a number of ways.  In a practical 
sense, many clinicians note that the main difficulty they had with SUDEP conversations was 
the limited time they had to discuss the information in addition to diagnosing epilepsy: 
‘so there's lots of things we have to talk about, or we feel pressure to talk about.  We 
have to talk about lots of different bits that's just one of the other things we have to 
talk about.’ (Registrar, Ss2) 
‘there is a lot to cover in a 30 minute consultation.  You take the history from the 
patient, sometimes from a witness of a possible event when they’ve lost consciousness.  
You’re asking them about their past medical history, you’re clinically examining 
them, you are going over investigations they may have had, if they’ve had imaging, 
you then sort of discuss the diagnosis you talk about drugs – you don’t have, it’s 
something that is kind of shoehorned in – you don’t have, it’s one of a list of things 
you need to do.’ (Consultant, Ss10) 
 
As a result of the limited time, clinicians wondered if this led to patients being ‘overloaded’ 
with information.  Clinicians wondered if this affected patients’ ability to understand their 
discussions about SUDEP.  This may also be the reason that patients accept the diagnosis so 
calmly: 
‘so by the time you come to it the patient already has a lot to absorb. And that’s why I 
think they’re already in their minds you know, trying to grasp as much information as 
they can, so they don’t immediately show a response that I have seen.’ (Registrar, 
Ss5) 
‘I think the new patients are sort of slightly numbed by the time you start to talk about 
it or are slightly overwhelmed already so they are less likely to engage and ask lots of 
questions about it I think, in my experience.’ (Registrar, Ss2) 
 
There was also a suggestion that the pressure clinicians are under in the initial session to 
correctly diagnose epilepsy may mean that SUDEP is not given the appropriate emphasis: 
‘So you’ve got a very limited time to try and sort of, we say getting the diagnosis right 
and conveying that to the patient is the primary aim.’ (Consultant, Ss7) 
 
In a broader sense clinicians noted their feelings regarding the pressure to discuss SUDEP as 
a result of the FAI.  Clinicians acknowledged the pressure they felt and questioned if the legal 
system should recommend medical advice to patients: 
‘and from my perspective too I also need to play safe from the medical legal point of 
view.’ (Consultant, Ss8) 
‘but whether one feels [discussing SUDEP] is appropriate or not, the fact is if you 
choose not to do it you're laying yourself open to risk - medical legal risk.’ 
(Consultant, Ss3) 
‘I think it's probably a bit unfortunate that the way we practice medicine, and this as 
an example, is not - the decision does not come from the doctors.’ (Consultant, Ss4) 
  
4. Discussion 
We report five main themes that accounted for Neurologists’ experiences when discussing 
SUDEP.  Neurologists appear to employ a standardized way of discussing SUDEP (‘the 
SUDEP protocol’); the recommendations of the FAI have diffused into their practice through 
meetings and training; Neurologists feel that discussing SUDEP has both negative and 
positive aspects to it; they report that patients are not distressed by SUDEP information, 
although they appear to be concerned that it will be distressing for them; and there is concern 
that the pressure to discuss SUDEP information soon after diagnosis may hinder 
communication.  Our study corroborates other recent research, which suggests that 
Neurologists in Scotland regularly discuss SUDEP with newly diagnosed epilepsy patients 
[13, 24].  Additionally, our study suggests that SUDEP is not routinely discussed with 
historically diagnosed epilepsy patients.  This may reflect that the FAI and guidelines refer to 
newly diagnosed patients only and have not explicitly stated that SUDEP be discussed with 
chronic epilepsy patients [27]. 
 
4.1 Guidelines versus Legal Recommendations 
The FAI has had an impact on Neurologists’ practice in Scotland.  Even Neurologists 
unaware of the specific details of the FAI have had their practice impacted.  The FAI has 
created a pressure to discuss SUDEP that is exerted through meetings and discussions 
amongst Neurologists.  In contrast, Neurologists are less aware of the content of medical 
guidelines. This is in keeping with prior systematic reviews on the impact of guidelines on 
clinical practice. [33] Guidelines may be more successful when introduced alongside rigorous 
evaluations of their impact [34]. Our study would suggest that compared to medical 
guidelines, a FAI may have a greater ability to influence medical practice, perhaps because of 
perceived medico-legal implications on clinicians. 
The FAI has led to an individualised ‘protocol’ for Neurologists discussing SUDEP.  
Neurologists noted that many of the epilepsy diagnosis sessions take a similar format and 
SUDEP has been added to the list of ‘necessary’ topics to discuss.  Moreover, there appears 
to be a standardised way of discussing SUDEP towards the end of diagnosis sessions and a 
similar approach noted in terms of discussing a ‘risk of harm’, rather than death, and noting 
measures that patients can take to reduce risk.  The ‘SUDEP protocol’ for chronic epilepsy 
patients is not as detailed as the protocol for initial diagnosis.  
 
4.2 Impact of Anxiety 
 
The FAI has also met with some resistance from clinicians.  Miller et al. [19] reported that 
clinicians suggested it was ‘morally wrong’ to give information about SUDEP because it was 
poorly understood and difficult to prevent.  In our study, similar to other research findings 
[18], Neurologists suggested that SUDEP information potentially could make a patient 
anxious or distressed – and this was an unnecessary reaction given the low risk of SUDEP 
occurring.  A number of additional statements can be made about this finding: firstly, 
although clinicians in the current study were mindful of not creating an anxious response in 
patients, it was clear that they were not anxious about having the discussion themselves.  This 
is in concordance with other research which suggests that despite the difficulties involved, 
 doctors in general feel comfortable with BBN experiences [20].  Secondly, despite 
anticipating an anxious response from patients, there were almost no accounts of this 
occurring.  This finding is corroborated by Harden et al. [13] and Tonberg et al. [24] as 
patients in these studies reported that SUDEP information created only short-lived anxiety.  
There may be a suggestion that the cautious approach employed by clinicians, and their 
anticipation of anxiety, may create the circumstances and atmosphere which results in the 
calm response from patients.  The clinicians in the current study raised another possibility 
that the pressure to convey SUDEP information in the diagnosis session has resulted in 
impaired communication.  There was concern that the information about SUDEP will not be 
conveyed sympathetically or that patients will not be able to explore or understand the 
information in sufficient detail, given the emotional impact of having just received a 
diagnosis of epilepsy.   
 
4.3 How could SUDEP conversations make a difference? 
Neurologists felt that the conversations about SUDEP might possibly influence adherence to 
medication.  Medication adherence is a multi-factorial process with numerous studies 
investigating the impact of providing information, self-monitoring, psychological therapy and 
many more interventions [39].  Evidence would suggest that a conversation with a clinician 
would, at best, have only a modest influence on rates of medication adherence [40, 41].  
Qualitative research has highlighted that patients report their clinicians SUDEP conversations 
do not affect adherence decision [13, 24]  however it may be useful to quantifiably measure 
the behaviour change that results from SUDEP conversations. 
 
4.4 Limitations 
The participants in the study were volunteers and likely to be interested in the practices 
relevant to SUDEP.  This may have resulted in a more extreme view being expressed either 
in favour of or against current practice.  Participants expressed concern about medico-legal 
risk if they did not discuss SUDEP with newly diagnosed patients.  It would be 
understandable if Neurologists not practicing in the legally recommended way may have 
avoided participation in the study.  
Neurologists expressed support was available to them but was rarely used.   Exploring how 
clinicians utilise support from colleagues may be best met with an alternative methodology.  
Notably, it was felt that clinicians often appeared hesitant and in some cases avoidant when 
asked about how they utilise or require support.  An Interpretive Phenomological Analysis 
may be more suited to explore this hesitancy and to analyse how the participant is making 
sense of this phenomenon [43].   
 
4.5 Conclusions 
Neurologists are concerned about the impact of SUDEP information on patients and are 
interested in evaluating if SUDEP discussions make a difference to patients’ behaviour.   
Our study suggests limited impact of guidelines on medical practice and that legal 
recommendations have a higher impact on Neurologists’ practice in Scotland.  This research 
may provide a useful comparative model for countries, health boards or organisations that are 
considering guideline recommendations for how and when SUDEP is discussed with patients. 
 Our study suggests additional pressure and concerns can arise as a result of a ‘blanket’ 
approach to medical practice and that Neurologists value a sense of clinical autonomy [19].  
The perceived removal of clinical autonomy increased Neurologists’ concerns about the 
quality, emotional impact, and benefits of the SUDEP conversation.    
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 Appendix A: Interview Schedule 
 
These questions were designed to facilitate the conversation and often evolved to focus more 
on specific areas depending on the issues and themes encountered in initial interviews. 
 
Most questions were expanded with follow up prompts.  Examples of prompts are given in 
bullet points below.   
 
Demographics: 
 
Can you describe your role to me? 
 
How long have you been practicing in your current role? 
 
In a typical week or month, how many people would you discuss SUDEP with? 
 
Knowledge 
 
What can you tell me about SUDEP? 
 
What factors influence the risk? 
 Prompts: What controllable risks exist? What uncontrollable risks exist? 
 
Are there any guidelines that inform you about SUDEP and what to discuss with patients? 
 Prompts: What do SIGN/NICE guidelines say in the subject? 
 
Are there any local NHS policies that affect your practice with regards to SUDEP 
discussions? 
 Prompts: Can you tell me about these? 
 
Typically, what do patients know about SUDEP before you speak to them? 
 Prompt: What sources of information have you used? 
 
Practice/Intention 
 
“I am now interested in finding about your typical practice or how you would normally wish 
to discuss SUDEP with a patient” 
 
When would you typically first discuss SUDEP with a patient? 
 
What influences the timing of when you discuss SUDEP? 
 Prompt: are there times or situations when you won’t discuss SUDEP? 
 
How is the topic of SUDEP usually first raised? 
 
How do you feel when you know you are about to discuss SUDEP with a patient for the first 
time? 
 
What key messages do you hope that patients take away with them? 
 Prompt: Is there anything you do to help get these messages across to patients?  
  
Experience 
 
“I am interested in hearing about some specific experiences you have had discussing SUDEP 
with patients.” 
 
Can you tell me about the last time you discussed SUDEP with a patient or carer? 
 Prompts: Who initiated this discussion? 
 What did you tell the patient/carer about SUDEP? 
 What did the patient/carer ask about? What information did they already have? 
Where had they got this information from? 
 How did the patient/carer seem to react/cope with the discussion? 
 How did you feel about this discussion? 
 What did you do to cope with this discussion?  
 Looking back, is there anything you think you could have done/said 
differently? 
 Would you say this was typical as to how SUDEP is discussed?  
 
Can you tell me about a SUDEP discussion that particularly stands out as a difficult 
discussion? 
o Prompts: What was it that was difficult about this discussion? 
o Who initiated this discussion? 
o What did you tell the patient/carer about SUDEP? 
o What did the patient/carer ask about? What information did they already have? 
Where had they got this information from? 
o How did the patient/carer seem to react/cope with the discussion? 
o How did you feel about this discussion? 
o What did you do to cope with this discussion?  
o Looking back, is there anything you think you could have done/said 
differently? 
o Would you say this was typical as to how SUDEP is discussed?  
 
 
Can you tell me about a SUDEP discussion that particularly stands out as a good or positive 
discussion? 
o Prompts: What was it that was positive about this discussion? 
o Who initiated this discussion? 
o What did you tell the patient/carer about SUDEP? 
o What did the patient/carer ask about? What information did they already have? 
Where had they got this information from? 
o How did the patient/carer seem to react/cope with the discussion? 
o How did you feel about this discussion? 
o What did you do to cope with this discussion?  
o Looking back, is there anything you think you could have done/said 
differently? 
o Would you say this was typical as to how SUDEP is discussed?  
 
Reflection/thoughts on the future 
 
 “I would like to hear some of your reflections on your experiences and any thoughts about 
what could support your practice.” 
 
Looking back on your experiences, what could make SUDEP discussions easier for you or 
the patient? 
 In particular, are there any resources or training courses that could help? 
 
Has your way of discussing SUDEP changed over time? 
 
How do your discussions about SUDEP compare with other times you have had to discuss 
other ‘bad news’ with a patient? 
 
If you had a difficult experience discussing SUDEP what would you do? 
Prompts: Is there anyone you would go to for support? 
 Is there anything else you would do following a difficult experience? 
 
How do your SUDEP discussions make a difference to patients’ behaviour? 
 
What advice would you give to a junior colleague regarding how to have SUDEP 
conversations and what to say? 
 
  
 Appendix B: The SUDEP protocol diagram 
 
 
 
Epilepsy diagnosis - medication 
choices - lifestyle impact - SUDEP
Won't discuss if patient 
distressed by diagnosis
SUDEP usually raised by clinician
Use of standard 'script'/phrase
May not use the word 'death' -
discuss in terms of risk/harm
Risks for SUDEP 
(lifestyle/nocturnal seizures)
Will usually document 
conversation to GP
Epilepsy Nurses can discuss in 
more detail
